PTC Therapeutics logo

PTC TherapeuticsNASDAQ: PTCT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 June 2013

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$3.19 B
-27%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
6%vs. sector
-48%vs. 3y high
53%vs. sector

Price

pre-market | 13 min ago
$41.31-$0.64(-1.53%)

Dividend

No data over the past 3 years
$196.79 M$190.47 M
$196.79 M-$106.65 M

Analysts recommendations

Institutional Ownership

PTCT Latest News

PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: NEUTRAL

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Michael Riad - Morgan Stanley Brian Abraham - RBC Capital Markets Ellie Merle - UBS Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Paul Choi - Goldman Sachs Gena Wang - Barclays Danielle Brill - Raymond James Joseph Schwartz - Leerink Partners Operator Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CHMP Maintains Negative Opinion on Translarna™ Reexamination
prnewswire.com18 October 2024 Sentiment: NEGATIVE

- Opinion to be reviewed by European Commission - WARREN, N.J. , Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne Muscular Dystrophy (nmDMD) following re-examination.

PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
zacks.com09 October 2024 Sentiment: POSITIVE

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
zacks.com09 October 2024 Sentiment: POSITIVE

PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ron Aldridge – Senior Director of Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph – J.P. Morgan Kelly Shi – Jefferies Samantha Corwin - William Blair Brian Abraham - RBC Capital Markets Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gena Wang – Barclays David Lebowitz – Citi Joseph Schwartz - Leerink Partners Operator Good day and thank you for standing by.

PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
zacks.com08 August 2024 Sentiment: NEGATIVE

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $2.66 per share a year ago.

PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today!
accesswire.com17 July 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / July 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.

PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into PTC Therapeutics, Inc and Encourages Investors to Contact the Firm Today!
accesswire.com16 July 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / July 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
globenewswire.com15 July 2024 Sentiment: NEGATIVE

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.

What type of business is PTC Therapeutics?

PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for the treatment of rare diseases. PTC Therapeutics, Inc. was founded in 1998, with its headquarters located in South Plainfield, New Jersey. PTC Therapeutics offers products such as Translarna and Emflaza for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; Tegsedi and Waylivra for the treatment of rare diseases in Latin American and Caribbean countries. The company is also developing a range of gene therapy candidates for the treatment of rare monogenic diseases affecting the central nervous system, including PTC-AADC for the treatment of a rare CNS disorder resulting from reduction.

What sector is PTC Therapeutics in?

PTC Therapeutics is in the Healthcare sector

What industry is PTC Therapeutics in?

PTC Therapeutics is in the Biotechnology industry

What country is PTC Therapeutics from?

PTC Therapeutics is headquartered in United States

When did PTC Therapeutics go public?

PTC Therapeutics initial public offering (IPO) was on 20 June 2013

What is PTC Therapeutics website?

https://www.ptcbio.com

Is PTC Therapeutics in the S&P 500?

No, PTC Therapeutics is not included in the S&P 500 index

Is PTC Therapeutics in the NASDAQ 100?

No, PTC Therapeutics is not included in the NASDAQ 100 index

Is PTC Therapeutics in the Dow Jones?

No, PTC Therapeutics is not included in the Dow Jones index

When was PTC Therapeutics the previous earnings report?

No data

When does PTC Therapeutics earnings report?

The next expected earnings date for PTC Therapeutics is 28 February 2025